Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia

Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up

Giuseppe Avvisati, Maria Concetta Petti, Francesco Lo-Coco, Maria Luce Vegna, Sergio Amadori, Michele Baccarani, Nicola Cantore, Eros Di Bona, Felicetto Ferrara, Giuseppe Fioritoni, Eugenio Gallo, Rosangela Invernizzi, Mario Lazzarino, Vincenzo Liso, Guglielmo Mariani, Francesco Ricciuti, Carmine Selleri, Simona Sica, Dino Veneri, Franco Mandelli

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Shortly before the all-trans retinoic acid (ATRA) era, the GIMEMA cooperative group initiated a randomized study comparing idarubicin (IDA) alone with IDA plus arabinosylcytosine (Ara-C) as induction treatment in patients with newly diagnosed hypergranular acute promyelocytic leukemia (APL). Of the 257 patients evaluable for induction treatment, 131 were randomized to receive IDA alone (arm A) and 126 to receive IDA + Ara-C (arm B). Treatment in arm A consisted of 10 mg/m2 IDA daily for 6 consecutive days, whereas in arm B it consisted of 12 mg/m2 IDA daily for 4 days combined with 200 mg/m2 Ara-C daily in continuous infusion for 7 days. Once in complete remission (CR), patients received 3 consolidation courses of standard chemotherapy, and those still in CR at the end of the consolidation were randomized to receive or not receive 1 mg/kg 6-mercaptopurine daily and intramuscular injections of 0.25 mg/kg methotrexate weekly for 2 years. Overall, 100 (76.3%) patients in arm A and 84 (66.6%) patients in arm B achieved CR (P= NS). Event-free survival (EFS) rates were 35% and 23% for patients in arm A and arm B, respectively (P = .0352). Multivariate analysis revealed that EFS was favorably influenced by induction treatment with IDA alone (P = .0352) and unfavorably influenced by white blood cell (WBC) counts greater than 3000/μL (P = .0001) and increasing age (P = .0251). These results indicate that anthracycline monochemotherapy with IDA favorably influences the EFS of patients with newly diagnosed hypergranular APL.

Original languageEnglish
Pages (from-to)3141-3146
Number of pages6
JournalBlood
Volume100
Issue number9
DOIs
Publication statusPublished - Nov 1 2002

Fingerprint

Idarubicin
Acute Promyelocytic Leukemia
Disease-Free Survival
Cytarabine
Therapeutics
Consolidation
6-Mercaptopurine
Chemotherapy
Anthracyclines
Intramuscular Injections
Tretinoin
Leukocyte Count
Methotrexate
Blood
Multivariate Analysis
Survival Rate
Cells
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia : Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. / Avvisati, Giuseppe; Petti, Maria Concetta; Lo-Coco, Francesco; Vegna, Maria Luce; Amadori, Sergio; Baccarani, Michele; Cantore, Nicola; Bona, Eros Di; Ferrara, Felicetto; Fioritoni, Giuseppe; Gallo, Eugenio; Invernizzi, Rosangela; Lazzarino, Mario; Liso, Vincenzo; Mariani, Guglielmo; Ricciuti, Francesco; Selleri, Carmine; Sica, Simona; Veneri, Dino; Mandelli, Franco.

In: Blood, Vol. 100, No. 9, 01.11.2002, p. 3141-3146.

Research output: Contribution to journalArticle

Avvisati, G, Petti, MC, Lo-Coco, F, Vegna, ML, Amadori, S, Baccarani, M, Cantore, N, Bona, ED, Ferrara, F, Fioritoni, G, Gallo, E, Invernizzi, R, Lazzarino, M, Liso, V, Mariani, G, Ricciuti, F, Selleri, C, Sica, S, Veneri, D & Mandelli, F 2002, 'Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up', Blood, vol. 100, no. 9, pp. 3141-3146. https://doi.org/10.1182/blood-2002-02-0352
Avvisati, Giuseppe ; Petti, Maria Concetta ; Lo-Coco, Francesco ; Vegna, Maria Luce ; Amadori, Sergio ; Baccarani, Michele ; Cantore, Nicola ; Bona, Eros Di ; Ferrara, Felicetto ; Fioritoni, Giuseppe ; Gallo, Eugenio ; Invernizzi, Rosangela ; Lazzarino, Mario ; Liso, Vincenzo ; Mariani, Guglielmo ; Ricciuti, Francesco ; Selleri, Carmine ; Sica, Simona ; Veneri, Dino ; Mandelli, Franco. / Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia : Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. In: Blood. 2002 ; Vol. 100, No. 9. pp. 3141-3146.
@article{4292c8495e2f4b158a0c4b3f4bf1628b,
title = "Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up",
abstract = "Shortly before the all-trans retinoic acid (ATRA) era, the GIMEMA cooperative group initiated a randomized study comparing idarubicin (IDA) alone with IDA plus arabinosylcytosine (Ara-C) as induction treatment in patients with newly diagnosed hypergranular acute promyelocytic leukemia (APL). Of the 257 patients evaluable for induction treatment, 131 were randomized to receive IDA alone (arm A) and 126 to receive IDA + Ara-C (arm B). Treatment in arm A consisted of 10 mg/m2 IDA daily for 6 consecutive days, whereas in arm B it consisted of 12 mg/m2 IDA daily for 4 days combined with 200 mg/m2 Ara-C daily in continuous infusion for 7 days. Once in complete remission (CR), patients received 3 consolidation courses of standard chemotherapy, and those still in CR at the end of the consolidation were randomized to receive or not receive 1 mg/kg 6-mercaptopurine daily and intramuscular injections of 0.25 mg/kg methotrexate weekly for 2 years. Overall, 100 (76.3{\%}) patients in arm A and 84 (66.6{\%}) patients in arm B achieved CR (P= NS). Event-free survival (EFS) rates were 35{\%} and 23{\%} for patients in arm A and arm B, respectively (P = .0352). Multivariate analysis revealed that EFS was favorably influenced by induction treatment with IDA alone (P = .0352) and unfavorably influenced by white blood cell (WBC) counts greater than 3000/μL (P = .0001) and increasing age (P = .0251). These results indicate that anthracycline monochemotherapy with IDA favorably influences the EFS of patients with newly diagnosed hypergranular APL.",
author = "Giuseppe Avvisati and Petti, {Maria Concetta} and Francesco Lo-Coco and Vegna, {Maria Luce} and Sergio Amadori and Michele Baccarani and Nicola Cantore and Bona, {Eros Di} and Felicetto Ferrara and Giuseppe Fioritoni and Eugenio Gallo and Rosangela Invernizzi and Mario Lazzarino and Vincenzo Liso and Guglielmo Mariani and Francesco Ricciuti and Carmine Selleri and Simona Sica and Dino Veneri and Franco Mandelli",
year = "2002",
month = "11",
day = "1",
doi = "10.1182/blood-2002-02-0352",
language = "English",
volume = "100",
pages = "3141--3146",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia

T2 - Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up

AU - Avvisati, Giuseppe

AU - Petti, Maria Concetta

AU - Lo-Coco, Francesco

AU - Vegna, Maria Luce

AU - Amadori, Sergio

AU - Baccarani, Michele

AU - Cantore, Nicola

AU - Bona, Eros Di

AU - Ferrara, Felicetto

AU - Fioritoni, Giuseppe

AU - Gallo, Eugenio

AU - Invernizzi, Rosangela

AU - Lazzarino, Mario

AU - Liso, Vincenzo

AU - Mariani, Guglielmo

AU - Ricciuti, Francesco

AU - Selleri, Carmine

AU - Sica, Simona

AU - Veneri, Dino

AU - Mandelli, Franco

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Shortly before the all-trans retinoic acid (ATRA) era, the GIMEMA cooperative group initiated a randomized study comparing idarubicin (IDA) alone with IDA plus arabinosylcytosine (Ara-C) as induction treatment in patients with newly diagnosed hypergranular acute promyelocytic leukemia (APL). Of the 257 patients evaluable for induction treatment, 131 were randomized to receive IDA alone (arm A) and 126 to receive IDA + Ara-C (arm B). Treatment in arm A consisted of 10 mg/m2 IDA daily for 6 consecutive days, whereas in arm B it consisted of 12 mg/m2 IDA daily for 4 days combined with 200 mg/m2 Ara-C daily in continuous infusion for 7 days. Once in complete remission (CR), patients received 3 consolidation courses of standard chemotherapy, and those still in CR at the end of the consolidation were randomized to receive or not receive 1 mg/kg 6-mercaptopurine daily and intramuscular injections of 0.25 mg/kg methotrexate weekly for 2 years. Overall, 100 (76.3%) patients in arm A and 84 (66.6%) patients in arm B achieved CR (P= NS). Event-free survival (EFS) rates were 35% and 23% for patients in arm A and arm B, respectively (P = .0352). Multivariate analysis revealed that EFS was favorably influenced by induction treatment with IDA alone (P = .0352) and unfavorably influenced by white blood cell (WBC) counts greater than 3000/μL (P = .0001) and increasing age (P = .0251). These results indicate that anthracycline monochemotherapy with IDA favorably influences the EFS of patients with newly diagnosed hypergranular APL.

AB - Shortly before the all-trans retinoic acid (ATRA) era, the GIMEMA cooperative group initiated a randomized study comparing idarubicin (IDA) alone with IDA plus arabinosylcytosine (Ara-C) as induction treatment in patients with newly diagnosed hypergranular acute promyelocytic leukemia (APL). Of the 257 patients evaluable for induction treatment, 131 were randomized to receive IDA alone (arm A) and 126 to receive IDA + Ara-C (arm B). Treatment in arm A consisted of 10 mg/m2 IDA daily for 6 consecutive days, whereas in arm B it consisted of 12 mg/m2 IDA daily for 4 days combined with 200 mg/m2 Ara-C daily in continuous infusion for 7 days. Once in complete remission (CR), patients received 3 consolidation courses of standard chemotherapy, and those still in CR at the end of the consolidation were randomized to receive or not receive 1 mg/kg 6-mercaptopurine daily and intramuscular injections of 0.25 mg/kg methotrexate weekly for 2 years. Overall, 100 (76.3%) patients in arm A and 84 (66.6%) patients in arm B achieved CR (P= NS). Event-free survival (EFS) rates were 35% and 23% for patients in arm A and arm B, respectively (P = .0352). Multivariate analysis revealed that EFS was favorably influenced by induction treatment with IDA alone (P = .0352) and unfavorably influenced by white blood cell (WBC) counts greater than 3000/μL (P = .0001) and increasing age (P = .0251). These results indicate that anthracycline monochemotherapy with IDA favorably influences the EFS of patients with newly diagnosed hypergranular APL.

UR - http://www.scopus.com/inward/record.url?scp=0036838645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036838645&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-02-0352

DO - 10.1182/blood-2002-02-0352

M3 - Article

VL - 100

SP - 3141

EP - 3146

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -